- Home
- RLMD vs ENTA Comparison
RLMD vs ENTA Comparison
Compare RLMD & ENTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RLMD
- ENTA
- Stock Information
- Founded
- RLMD 2004
- ENTA 1995
- Country
- RLMD United States
- ENTA United States
- Employees
- RLMD N/A
- ENTA N/A
- Industry
- RLMD Biotechnology: Pharmaceutical Preparations
- ENTA Biotechnology: Pharmaceutical Preparations
- Sector
- RLMD Health Care
- ENTA Health Care
- Exchange
- RLMD Nasdaq
- ENTA Nasdaq
- Market Cap
- RLMD 289.7M
- ENTA 316.2M
- IPO Year
- RLMD N/A
- ENTA 2013
- Fundamental
- Price
- RLMD $3.98
- ENTA $12.13
- Analyst Decision
- RLMD Hold
- ENTA Strong Buy
- Analyst Count
- RLMD 2
- ENTA 6
- Target Price
- RLMD $1.00
- ENTA $20.33
- AVG Volume (30 Days)
- RLMD 1.8M
- ENTA 432.1K
- Earning Date
- RLMD 11-13-2025
- ENTA 11-17-2025
- Dividend Yield
- RLMD N/A
- ENTA N/A
- EPS Growth
- RLMD N/A
- ENTA N/A
- EPS
- RLMD N/A
- ENTA N/A
- Revenue
- RLMD N/A
- ENTA $64,806,000.00
- Revenue This Year
- RLMD N/A
- ENTA $0.07
- Revenue Next Year
- RLMD N/A
- ENTA N/A
- P/E Ratio
- RLMD N/A
- ENTA N/A
- Revenue Growth
- RLMD N/A
- ENTA N/A
- 52 Week Low
- RLMD $0.24
- ENTA $4.09
- 52 Week High
- RLMD $4.34
- ENTA $15.34
- Technical
- Relative Strength Index (RSI)
- RLMD 78.00
- ENTA 62.83
- Support Level
- RLMD $2.42
- ENTA $11.61
- Resistance Level
- RLMD $2.86
- ENTA $12.47
- Average True Range (ATR)
- RLMD 0.43
- ENTA 0.69
- MACD
- RLMD 0.15
- ENTA 0.07
- Stochastic Oscillator
- RLMD 82.19
- ENTA 78.95
About RLMD Relmada Therapeutics Inc.
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its key product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.
About ENTA Enanta Pharmaceuticals Inc.
Enanta Pharmaceuticals Inc is an American biotechnology company which uses robust, chemistry-driven approach and drug discovery capabilities to focus on the research and development of molecule drugs to cure viral infections and liver diseases. Uses virology and immunology method for curing the diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.